4/A: Heron Therapeutics Director Waage Receives Stock Options and Restricted Stock Units

Director Christian Waage of Heron Therapeutics received stock options and restricted stock units on January 31, 2025, according to a Form 4/A filing with the SEC.

Summary

• Christian Waage, a director at Heron Therapeutics, received 17,950 restricted stock units and options to purchase 35,900 shares of common stock on January 31, 2025.
• The restricted stock units vest in full on January 31, 2026, and each unit represents the right to receive one share of common stock.
• The stock options, with an exercise price of $1.70, vest in 12 equal monthly installments starting one month after the grant date and expire on January 31, 2035.
• Following these transactions, Waage directly owns 84,130 shares of Heron Therapeutics common stock and options to purchase 35,900 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The grant of stock options and restricted stock units is a standard practice and generally viewed as a positive incentive for management.

Positives

• The grant of stock options and restricted stock units aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Future Outlook

There is no future outlook provided in this document.

Industry Context

Stock option and restricted stock unit grants are common practices for compensating and incentivizing directors and executives in publicly traded companies, particularly in the biotechnology and pharmaceutical industries.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in the pharmaceutical industry, similar to companies like Amgen and Gilead Sciences, where equity-based compensation is used to align director interests with shareholder value.
• The vesting schedule of the restricted stock units, vesting in full after one year, is relatively standard, comparable to vesting schedules seen at companies like Regeneron Pharmaceuticals.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign, aligning the director's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Heron Therapeutics, Director, Christian Waage, Stock Options, Restricted Stock Units, Form 4, SEC Filing, HRTX, Beneficial Ownership